Navigation Links
D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
Date:3/4/2008

REHOVOT, Israel, March 4 /PRNewswire/ -- D-Pharm announced today that it has held its Pre-IND (Investigational New Drug) meeting with the FDA to discuss the forthcoming IND submission for DP-b99, a novel drug to aid recovery following acute stroke. The Pre-IND meeting focused on the proposed plans for the Phase III clinical program and the discussion included clinical trials to date, preclinical pharmacology, toxicology data and the FDA requirements and suggestions for the IND submission. DP-b99 is a unique drug protecting brain cells in stroke patients, discovered and developed by D-Pharm.

Alex Kozak, PhD, President and CEO of D-Pharm, said "The positive and constructive feed-back we've received from the FDA is most encouraging. With a number of uncertainties in the developmental program removed we may now follow a clear path towards an IND application for a pivotal Phase III study towards the end of this year. This is good news for D-Pharm and for stroke patients."

Most recently, D-Pharm successfully completed a Phase IIb trial for DP-b99 in 150 ischemic stroke patients. Results from this study will be published shortly in the peer reviewed journal, Stroke. DP-b99 statistically significantly increased by two-fold the percentage of patients that completely recovered from ischemic stroke. In addition, DP-b99 has at least a 9hr therapeutic window and may be safely administered in this patient population.

D-Pharm has commenced preparations for the pivotal Phase III trial, including manufacturing of the drug, certain customary studies and IND submission. The Phase III trial is expected to commence in 2009 and to recruit about 750 moderately severe acute stroke patients in North America, Europe and Asia. D-Pharm will be seeking a suitable CRO for the next study with DP-b99. Interested CROs can find more details by following this link:

http://www.dpharm.com/docs/reports/Call_for_proposals_for_DP-b99_Ph_III _s

tudy.pdf

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

About Stroke

Every year approximately 750,000 Americans have a new or recurrent stroke. The second most common cause of death worldwide, stroke is also the leading cause of serious long-term disability; 15% to 30% of stroke survivors experience permanent disability. According to the American Heart Association, the mean lifetime cost resulting from an ischemic stroke is estimated at $140,000 per patient. Other than tissue plasminogen activator (tPA), which must be administered 3 hours after stroke, there are no FDA approved medicines for this indication.

About D-Pharm Ltd.

D-Pharm (http://www.dpharm.com) is clinical stage biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm's pipeline includes advanced clinical stage products, DP-b99 and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and migraine prophylaxis, currently in Phase II development. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer's disease. Other mimics of bioactive lipids, LipidoMimetix, are at an earlier developmental stage, for cancer.

For further information please contact:

Tami Horovitz, PhD.

Tel: +972-8-9385100

Fax: +972-8-9300795

Email: thorovitz@dpharm.com


'/>"/>
SOURCE D-Pharm Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Plurality Completes R&D of its HAL-256 Multicore Processor
2. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
3. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
4. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
5. Cardium Completes $5.3 Million Registered Direct Offering
6. WuXi PharmaTech Completes Acquisition of AppTec
7. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
8. Healionics Corporation Completes Series A Financing
9. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
10. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
11. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... ... sources for advanced technology applications, has announced a facility expansion to accommodate its ... 3,000 square feet of new workspace and renovation of the existing areas. The ...
(Date:5/23/2017)... ... May 23, 2017 , ... Customers often prefer PLC ... and again. METTLER TOLEDO has released two new videos that show how they ... of the ACT350 into Siemens and Allen Bradley PLCs is easy and fast. ...
(Date:5/21/2017)... ... 19, 2017 , ... Ovation Fertility scientists’ work is being ... Bioanalysts (AAB) and the College of Reproductive Biology (CRB) today and Saturday (May ... excellence in clinical laboratory services and regulations. , “We are pleased to ...
(Date:5/18/2017)... ... May 18, 2017 , ... ... April 28, 2017 at the Prince Of Wales Private Hospital. The procedure was ... level C6-C7. The patient failed conservative treatments prior to undergoing surgery. , The ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):